Top 15. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other ...

Bristol-Myers Squibb Company ( NYSE:BMY ) stock is about to trade ex-dividend in two days. The ex-dividend date is ...

Bristol-Myers Squibb's stock is set to rise with FDA approvals, acquisitions, and a strong oncology portfolio, despite ...

Given its better valuation, we believe that Bristol Myers Squibb stock (NYSE: BMY) is currently a better pick than its peer – ...

Bristol-Myers Squibb's acquisition of Karuna and FDA approval of Cobenfy signal growth potential, with focus on driving ...

Morgan Stanley analyst Terence Flynn has maintained their neutral stance on PRME stock, giving a Hold rating today. Terence Flynn’s ...

On Friday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $50.91 which represents a slight increase of $0.79 or 1.58% from the prior close of $50.12. The stock opened at ...

Below is Validea's guru fundamental report for BRISTOL-MYERS SQUIBB CO (BMY). Of the 22 guru strategies we follow, BMY rates highest using our P/B Growth Investor model based on the published ...

As of now, Bristol Myers Squibb has registered a Year-to-Date (YTD) stock performance of +1.48%. This figure starkly contrasts with the S&P 500’s impressive YTD performance of +20.45%. While BMY’s ...

In a report released today, Srikripa Devarakonda from Truist Financial assigned a Buy rating to Bristol-Myers Squibb (BMY – Research ...

Bristol-Myers Squibb Co (NYSE:BMY) is up 3.2% at $51.71, after the U.S. Food & Drug Administration (FDA) approved the pharma ...

Shares in Bristol-Myers Squibb (BMY) surged Friday, after the Food and Drug Administration approved the drugmaker's novel ...